Free Stadium Blanket. Join for Life.

Drugs Showing Promise in Cancer Trials Reduce Scarring for Scleroderma

May 6, 2022

 • 

Read time:

<5 mins
Microscope
Presented by Health Lab

A team of researchers from Michigan Medicine found a new purpose for epigenetic drugs and a potential treatment option for patients with scleroderma. This chronic disease affects the immune system, causing a buildup of scar-like tissues in the skin and internal organs known as fibrosis. Pen-Suen Tsou (Eliza), Ph.D., senior author and a rheumatology researcher at Michigan Medicine, explains how this new class of epigenetic drugs could significantly reduce scarring in the cells of patients with scleroderma.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.